Construction of a nomogram prediction model for evaluating the therapeutic efficacy of hyperbaric oxygen chamber therapy in managing acute radiation dermatitis among breast cancer patients

doi:10.3760/cma.j.cn371439-20251015-00075

Abstract

Abstract:

Objective To analyze the factors affecting the efficacy of hyperbaric oxygen chamber in treating acute radiation dermatitis （ARD） caused by breast cancer radiotherapy， and to construct a nomogram prediction model. Methods A total of 720 breast cancer patients who underwent modified radical mastectomy and radiotherapy in the Department of Radiation Oncology of the First Affiliated Hospital of Hebei North University from December 2021 to December 2024 were selected as research subjects. Using the random drawing method， patients were divided into the model group （n=504） and the validation group （n=216） in a ratio of 7∶3. On the basis of conventional ARD prevention measures， the patients received 15 sessions of hyperbaric oxygen chamber therapy. At week 7， multivariate logistic regression was used to analyze the influencing factors for patients with ARD grade 1 in the model group. A efficacy nomogram prediction model was constructed. The model's consistency was assessed using the C-index and calibration curves. Receiver operator characteristic （ROC） curve was plotted for patients with grade 1 ARD in both the model group and the validation group， and the area under the curve （AUC） was compared between groups using the DeLong test. Results There were statistically significant differences in age （t=-9.05， P<0.001）， history of chemotherapy （χ²=4.47， P=0.035）， hypertension （χ²=5.40， P=0.020）， diabetes （χ²=5.34， P=0.021）， microcirculation disorder （χ²=4.14， P=0.042）， and arteriosclerosis （χ²=4.12， P=0.042） between patients with grade 1 and grade 2 or above ARD at the 7th week of radiotherapy. Multivariate analysis revealed that age （OR=1.56， 95%CI： 1.09-1.93， P=0.031）， history of chemotherapy （OR=2.30， 95%CI： 1.66-4.78， P<0.001）， hypertension （OR=1.79， 95%CI： 1.24-2.78， P=0.026）， diabetes （OR=1.88， 95%CI： 1.39-3.25， P=0.019）， microcirculation disorder （OR=2.15， 95%CI： 1.58-4.46， P=0.004）， and atherosclerosis （OR=2.01， 95%CI： 1.49-4.27， P=0.010） were all independent influencing factors for grade 1 ARD in breast cancer patients at the 7th week of radiotherapy after radical mastectomy. The C-index of the nomogram prediction model constructed based on the above factors was 0.862 （95%CI： 0.824-0.895）， and the calibration curve showed good consistency （χ²=5.89， P=0.177）. The AUCs of the nomogram model for predicting grade 1 ARD in breast cancer patients at the 7th week of radiotherapy after radical mastectomy in the model group and validation group were 0.852 and 0.839， respectively， with no statistically significant difference （Z=0.48， P=0.328）. Conclusions For patients aged 51 or younger， without a history of chemotherapy， without hypertension， without diabetes， without microcirculation disorders， without arteriosclerosis， and who have developed ARD after radical mastectomy for breast cancer， hyperbaric oxygen chamber therapy demonstrates a relatively favorable therapeutic outcome. A nomogram prediction model developed based on the above factors is helpful for timely and accurately screening patients suitable for this intervention， offering certain clinical applicability and reference value.

Key words: Breast neoplasms, Chemoradiotherapy, Radiodermatitis, Hyperbaric oxygen

Niu Ping, Tian Long, Cui Ling. Construction of a nomogram prediction model for evaluating the therapeutic efficacy of hyperbaric oxygen chamber therapy in managing acute radiation dermatitis among breast cancer patients[J]. Journal of International Oncology, 2026, 53(8): 464-469.

Figures/Tables 5

References 18

[1]	王莉, 肖翰, 黄国福. 环状RNA在三阴性乳腺癌中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2024, 51(12): 774-778. DOI: 10.3760/cma.j.cn371439-20240702-00131.
[2]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149. DOI: 10.3760/cma.j.cn371439-20230116-00029.
[3]	Liu ZG, Wang XR, Wu ZY, et al. HBOT has a better cognitive outcome than NBH for patients with mild traumatic brain injury: a randomized controlled clinical trial[J]. Medicine (Baltimore), 2023, 102(37): e35215. DOI: 10.1097/MD.0000000000035215.
[4]	Xie YX, Hu T, Chen RW, et al. Predicting acute radiation dermatitis in breast cancer: a prospective cohort study[J]. BMC Cancer, 2023, 23(1): 537. DOI: 10.1186/s12885-023-10821-6. pmid: 37308936
[5]	Han XC, He Y, Yuan XN, et al. Hyperbaric oxygen therapy for patients with fibromyalgia: a systematic review protocol[J]. BMJ Open, 2023, 13(6): e071092. DOI: 10.1136/bmjopen-2022-071092.
[6]	Anderson J, Fan FG. DIBH-IMRT for RTOG 1304, cancer of the left breast: a case study[J]. Med Dosim, 2021, 46(4): 356-359. DOI: 10.1016/j.meddos.2021.03.010. pmid: 33934976
[7]	朱乐莎, 张遵浩, 田龙. 乳腺癌患者急性放射性皮炎关联规则预测模型创建[J]. 辐射研究与辐射工艺学报, 2025, 43(1): 65-72. DOI: 10.11889/j.1000-3436.2024-0061.
[8]	袁春兰, 杨培金, 田卫兵. CTA、MRA在诊断糖尿病足患者下肢血管病变中的临床意义[J]. 中国CT和MRI杂志, 2025, 23(8): 186-188. DOI: 10.3969/j.issn.1672-5131.2025.08.052.
[9]	Zhong QX, Zhao YJ, Zeng L. The clinical effect of breast conservation surgery and modified radical mastectomy on breast cancer: a systematic review and meta-analysis[J]. Curr Probl Surg, 2025, 68: 101772. DOI: 10.1016/j.cpsurg.2025.101772.
[10]	Assaf GR, Yared F, Dib MJ, et al. Efficacy of opioid-free anesthesia in modified radical mastectomy: a cross-sectional observational study[J]. Ann Med Surg (Lond), 2023, 85(9): 4289-4292. DOI: 10.1097/MS9.0000000000000718. pmid: 37663699
[11]	胡秀茹, 许文秀, 张伟, 等. 高压氧喷联合贝复济治疗3/4级放射性皮炎的临床疗效观察[J]. 中国中西医结合皮肤性病学杂志, 2022, 21(5): 430-432. DOI: 10.3969/j.issn.1672-0709.2022.05.010.
[12]	Lee JY, Hyun MH, Yang G, et al. Efficacy and safety of hyperbaric oxygen therapy for radiation-induced dermatitis in patients with breast cancer: a randomized pilot study[J]. Support Care Cancer, 2025, 33(5): 399. DOI: 10.1007/s00520-025-09463-0. pmid: 40259026
[13]	Kim HR, Lee A, Choi EJ, et al. Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function[J]. PLoS One, 2014, 9(3): e91146. DOI: 10.1371/journal.pone.0091146.
[14]	Ruiz-Mambrilla M, Dueñas-Ruiz A, Pérez-Castrillón JL, et al. Speech therapy and hyperbaric oxygen for aphasia after carbon monoxide intoxication[J]. Undersea Hyperb Med, 2023, 50(1): 3-7. DOI: 10.22462/01.01.2023.15. pmid: 36820801
[15]	Zwoliński M, Hovagimyan A, Ignatowicz J, et al. The supporting role of hyperbaric oxygen therapy in atopic dermatitis treatment[J]. J Clin Med, 2025, 14(9): 3138. DOI: 10.3390/jcm14093138.
[16]	Lin ZC, Bennett MH, Hawkins GC, et al. Hyperbaric oxygen therapy for late radiation tissue injury[J]. Cochrane Database Syst Rev, 2023, 8(8): CD005005. DOI: 10.1002/14651858.CD005005.
[17]	Zhang YY, Zhou YJ, Jia YY, et al. Adverse effects of hyperbaric oxygen therapy: a systematic review and meta-analysis[J]. Front Med (Lausanne), 2023, 10: 1160774. DOI: 10.3389/fmed.2023.1160774.
[18]	Zhang L, Liu L, Li F, et al. Research trends and hot spots in the prevention and management of radiation dermatitis: a bibliometric analysis based on CiteSpace[J]. Radiat Oncol, 2025, 20(1): 55. DOI: 10.1186/s13014-025-02628-5. pmid: 40241141

临床资料	1级ARD （n=126）	2级及以上ARD （n=378）	t/χ²值	P值
年龄（岁，$ \bar{x} \pm s$）	46.38±15.56	56.88±9.44	-9.05	<0.001
KPS评分（分，$ \bar{x} \pm s$）	80.45±8.22	79.49±7.95	1.16	0.245
体质量指数（kg/m²，$ \bar{x} \pm s$）	26.89±6.45	25.94±5.32	1.64	0.101
化疗史[例（%）]
无	78（61.90）	193（51.04）	4.47	0.035
有	48（38.10）	185（48.96）	4.47	0.035
饮酒史[例（%）]
无	100（79.37）	311（82.28）	0.53	0.466
有	26（20.63）	67（17.72）	0.53	0.466
吸烟史[例（%）]
无	103（81.75）	325（85.98）	1.32	0.250
有	23（18.25）	53（14.02）	1.32	0.250
肿瘤分期[例（%）]
Ⅰ	75（59.52）	230（60.85）	0.32	0.853
Ⅱ	29（23.02）	90（23.81）
Ⅲ	22（17.46）	58（15.34）
肿瘤部位[例（%）]
左胸	59（46.83）	185（48.94）	0.17	0.681
右胸	67（53.17）	193（51.06）	0.17	0.681
肿瘤最大径（cm，$ \bar{x} \pm s$）	3.22±1.05	3.43±1.21	-1.74	0.082
最大照射野面积（cm²，$ \bar{x} \pm s$）	82.44±8.45	83.19±8.98	-0.82	0.411
子野数量（个，$ \bar{x} \pm s$）	52.25±5.89	53.37±6.67	-1.68	0.094
高血压[例（%）]
无	93（73.81）	236（62.43）	5.40	0.020
有	33（26.19）	142（37.57）	5.40	0.020
糖尿病[例（%）]
无	99（78.57）	256（67.72）	5.34	0.021
有	27（21.43）	122（32.28）	5.34	0.021
高血脂[例（%）]
无	101（80.16）	286（75.66）	1.07	0.300
有	25（19.84）	92（24.40）	1.07	0.300
微循环障碍[例（%）]
无	123（97.62）	350（92.59）	4.14	0.042
有	3（2.38）	28（7.41）	4.14	0.042
动脉粥样硬化[例（%）]
无	113（89.68）	310（82.01）	4.12	0.042
有	13（10.32）	68（17.99）	4.12	0.042

自变量	β值	SE值	Wald χ²值	OR值	95%CI	P值
年龄（≤51岁）	0.48	0.22	4.70	1.56	1.09~1.93	0.031
化疗史（无）	0.83	0.22	14.30	2.30	1.66~4.78	<0.001
高血压（无）	0.58	0.26	5.05	1.79	1.24~2.78	0.026
糖尿病（无）	0.63	0.27	5.48	1.88	1.39~3.25	0.019
微循环障碍（无）	0.77	0.29	7.21	2.15	1.58~4.46	0.004
动脉粥样硬化（无）	0.70	0.28	6.08	2.01	1.49~4.27	0.010